HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
International Institute for Zoonosis Control >
Peer-reviewed Journal Articles, etc >

Characterization of the In Vitro and In Vivo Efficacy of Baloxavir Marboxil against H5 Highly Pathogenic Avian Influenza Virus Infection

Files in This Item:

The file(s) associated with this item can be obtained from the following URL:

Title: Characterization of the In Vitro and In Vivo Efficacy of Baloxavir Marboxil against H5 Highly Pathogenic Avian Influenza Virus Infection
Authors: Taniguchi, Keiichi Browse this author
Ando, Yoshinori Browse this author
Kobayashi, Masanori Browse this author
Toba, Shinsuke Browse this author
Nobori, Haruaki Browse this author
Sanaki, Takao Browse this author
Noshi, Takeshi Browse this author
Kawai, Makoto Browse this author
Yoshida, Ryu Browse this author
Sato, Akihiko Browse this author
Shishido, Takao Browse this author
Naito, Akira Browse this author
Matsuno, Keita Browse this author →KAKEN DB
Okamatsu, Masatoshi Browse this author →KAKEN DB
Sakoda, Yoshihiro Browse this author →KAKEN DB
Kida, Hiroshi Browse this author →KAKEN DB
Keywords: baloxavir marboxil
viral replication
lung inflammation
combination therapy
Issue Date: Jan-2022
Publisher: MDPI
Journal Title: Viruses-Basel
Volume: 14
Issue: 1
Start Page: 111
Publisher DOI: 10.3390/v14010111
Abstract: Human infections caused by the H5 highly pathogenic avian influenza virus (HPAIV) sporadically threaten public health. The susceptibility of HPAIVs to baloxavir acid (BXA), a new class of inhibitors for the influenza virus cap-dependent endonuclease, has been confirmed in vitro, but it has not yet been fully characterized. Here, the efficacy of BXA against HPAIVs, including recent H5N8 variants, was assessed in vitro. The antiviral efficacy of baloxavir marboxil (BXM) in H5N1 virus-infected mice was also investigated. BXA exhibited similar in vitro activities against H5N1, H5N6, and H5N8 variants tested in comparison with seasonal and other zoonotic strains. Compared with oseltamivir phosphate (OSP), BXM monotherapy in mice infected with the H5N1 HPAIV clinical isolate, the A/Hong Kong/483/1997 strain, also caused a significant reduction in viral titers in the lungs, brains, and kidneys, thereby preventing acute lung inflammation and reducing mortality. Furthermore, compared with BXM or OSP monotherapy, combination treatments with BXM and OSP using a 48-h delayed treatment model showed a more potent effect on viral replication in the organs, accompanied by improved survival. In conclusion, BXM has a potent antiviral efficacy against H5 HPAIV infections.
Type: article
Appears in Collections:人獣共通感染症国際共同研究所 (International Institute for Zoonosis Control) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Export metadata:

OAI-PMH ( junii2 , jpcoar_1.0 )

MathJax is now OFF:


 - Hokkaido University